Human inner-ear hair cells do not naturally grow back after they are destroyed. NIDCD identifies this as one reason noise injury can produce permanent hearing loss. A gene-therapy result for a specific inherited condition should not be described as proof that missing hair cells have regenerated. 1
The question is biologically specific. “Restoring hearing” describes a desired function. “Regenerating hair cells” describes a possible route toward that function. A technology can improve the former without doing the latter.
Hair cells are part of a signal pathway
NIDCD's hearing explanation describes sensory cells converting movement within the cochlea into signals that can be transmitted through the auditory system. 2
For a regeneration claim, producing a cell-like structure would not by itself answer every functional question. Our evaluation framework would distinguish the new cell's identity, location, connection to the relevant pathway and contribution to measured hearing. Those are separate propositions, not a list of outcomes already achieved by a product.
This is why a microscopic image and a hearing test belong in different columns of an evidence record. Both may be important. Neither should silently stand in for the other.
Temporary recovery is not evidence of new cells
NIDCD notes that some noise-related hearing changes can resolve over a short period while warning that residual damage may still exist. Recovery after an exposure should not be interpreted as evidence that destroyed hair cells have been replaced. 1
That distinction matters in online discussions where “my hearing came back” is used to support a commercial regeneration claim. An observed change in function does not identify the biological mechanism that caused it.
This article is not guidance for evaluating an acute personal hearing change. It explains what can and cannot be concluded from the terminology.
What Otarmeni does differently
Otarmeni's U.S. indication is tied to molecularly confirmed OTOF-related loss and other ear-specific requirements. The label describes gene expression and otoferlin production rather than hair-cell replacement. 3 4
The April 2026 approval is therefore a meaningful gene-specific clinical development, not an announcement that every form of hair-cell loss can now be reversed. Read the OTOF mechanism explainer for the distinction between supplying a missing function and replacing a missing cell.
What hearing aids and cochlear implants do differently
Hearing aids amplify sound. Cochlear implants provide electrical stimulation through a device-mediated pathway. Neither description is a claim to regenerate destroyed hair cells. 5 6
Again, this is not a hierarchy of worth. A device can produce valuable practical benefit even when it does not biologically repair the tissue. A future regenerative treatment would need to establish its own benefits and risks rather than borrowing evidence from an existing device category.
How this site treats regeneration claims
We separate experiments in cells or animals from human evidence, and anatomical outcomes from hearing outcomes. A cell number, a molecular marker and a communication improvement would not be combined into one invented success score.
We also keep negative and incomplete evidence visible. If a source reports a mechanism without functional benefit, that is not the same as no biological effect; if function improves without a demonstrated regeneration mechanism, the improvement should not be mislabeled as regrowth.
The present clinical takeaway from the sources on this page is specific: a gene-specific treatment, an amplification device and an electrical implant are different from a demonstrated hair-cell-regeneration therapy. The broader hearing-restoration guide maps those distinctions without promising a universal cure.